Drugs / R3R01
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06600412 | Oct 2024 → Apr 2027 expected | diabetic kidney disease | River 3 Renal Corp. | Recruiting | No outcome recorded |
| Phase 2 | NCT05267262 | Jun 2022 → May 2025 | Alport syndrome, focal segmental glomerulosclerosis | River 3 Renal Corp. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | R3R01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06600412 ↗ |
| Modality | Small molecule | “investigational small molecule designed to decrease fat levels in certain cells in the kidney” NCT05267262 ↗ |
| Route | Oral | “R3R01 administered orally as 200 mg tablets twice daily for 84 days.” NCT05267262 ↗ |
| Target | ABCA1 | “R3R01 is an ATP-binding cassette transporter A1 (ABCA1) inducer” NCT06600412 ↗ |